Dopamine DA2-receptor activation inhibits noradrenaline release in human kidney slices

Rump, Lars C.; Schwertfeger, Eckhard; Schuster, Martin J.; Schaible, Ulrike; Frankenschmidt, Alexander; Schollmeyer, Peter J.
January 1993
Kidney International;Jan1993, Vol. 43 Issue 1, p197
Academic Journal
Dopamine receptor modulation of noradrenaline release from renal sympathetic nerves was investigated. Human kidney slices were incubated with ³H-noradrenaline, placed into superfusion chambers between two platinum electrodes and field-stimulated at 5 Hz. The slices accumulated radioactivity. Pretreatment of the kidney slices with 6-hydroxy-dopamine (1.2 mM) prior to the ³H-noradrenaline incubation reduced the accumulation of radioactivity. The stimulation induced (S-I) outflow of radioactivity was mainly composed of intact ³H-noradrenaline. The sodium channel blocker tetrodotoxin (1 μM), 6-hydroxy-dopamine pretreatment and omission of calcium from the superfusion solution abolished S-I outflow of radioactivity. The DA1-receptor agonist fenoldopam (SKF 82526; 0.01 and 0.1 μM) did not alter but fenoldopam (1 μM) increased S-I outflow of radioactivity. However, in the presence of either the non-selective α2-adrenoceptor antagonist phentolamine (1 μM) or the selective α2-adrenoceptor antagonist idazoxan (1 μM) fenoldopam (1 μM) had no effect. The DA2-receptor agonist quinpirole (LY 171555; 1 μM) inhibited S-I outflow of radioactivity, an effect blocked by the selective DA2-receptor antagonists S(-)-sulpiride ( 10 μM) and domperidone (0.3 μM) but unaltered either by the DA1-receptor antagonist SCH 23390 (1 μM) or by phentolamine (1 μM). The α2 -adrenoceptor agonist UK 14304 (0.1 μM) inhibited S-I outflow of radioactivity, and this effect was blocked by phentolamine (1 μM) and idazoxan (1 μM) but unaltered by S(-)-sulpiride (10 μM). Phentolamine and idazoxan, in contrast to S(-)-sulpiride, domperidone and SCH 23390, enhanced S-I outflow of radioactivity by themselves. The DA2-receptor agonist carmoxirole (EMD 45609:0.03 μM) inhibited S-I outflow of radioactivity but carmoxirole (0.003 and 0.3 μM) did not. However, in the presence of phentolamine carmoxirole (0.3 and 0.03 μM) inhibited S-I outflow of radioactivity to a similar extent. Moreover, in the presence of idazoxan carmoxirole (0.3 μM) also inhibited S-I outflow of radioactivity. The inhibitory effect of carmoxirole (0.03 μM) was blocked by S(-)-sulpiride (10 μM) but not by SCH 23390 (1 μM). The data suggest that activation of prejunctional DA2-receptors by either quinpirole or carmoxirole (0.03 μM) inhibits noradrenaline release in human kidney cortex. The inhibitory DA2-receptor mediated effect of carmoxirole (0.3 μM) seems to be masked by simultaneous blockade of prejunctional inhibitory a-autoreceptors. There is no evidence that activation of DA1-receptors modulates noradrenaline release. Endogenous noradrenaline, in contrast to endogenous dopamine, seems to activate its respective prejunctional receptor system, since phentolamine and idazoxan but neither S(-)-sulpiride nor domperidone enhanced S-I outflow of radioactivity.


Related Articles

  • D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats. Bhattacharjee, Abesh Kumar; Chang, Lisa; Ho-Joo Lee; Bazinet, Richard P.; Seemann, Ruth; Rapoport, Stanley I. // Psychopharmacology;Aug2005, Vol. 180 Issue 4, p735 

    Focuses on a study which measured the signaling in response to dopamine D1 and D2 receptor agonists given acutely to unanesthetized rats using in vivo fatty acid method. Review of literature on dopamine receptors; Effects of drugs on AA incorporation coefficients for arachidonic acid;...

  • dopamine-receptor stimulant (Major drug group).  // Royal Society of Medicine: Medicines;2002, p215 

    This article presents information on the drug dopamine-receptor stimulant í‘– which act to mimic the actions of dopamine in the body, where it is a neurotransmitter, mainly in the brain. The most important example of the latter is levodopa which is converted into dopamine in the body, and...

  • Effect of quinpirole on timing behaviour in the free-operant psychophysical procedure: evidence for the involvement of D2 dopamine receptors. Cheung, T. H. C.; Bezzina, G.; Hampson, C. L.; Body, S.; Fone, K. C. F.; Bradshaw, C. M.; Szabadi, E. // Psychopharmacology;Aug2007, Vol. 193 Issue 3, p423 

    Operant timing behaviour is sensitive to dopaminergic manipulations. It has been proposed that this effect is mediated principally by D2-like dopamine receptors. However, we recently found that the effect of d-amphetamine on timing in the free-operant psychophysical procedure was mediated by...

  • SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity. Depoortere, Ronan; Boulay, Denis; Perrault, Ghislaine; Bergis, Olivier; Decobert, Michel; Françon, Dominique; Jung, Mireille; Simiand, Jacques; Soubrié, Philippe; Scatton, Bernard // Neuropsychopharmacology;Nov2003, Vol. 28 Issue 11, p1889 

    SSR181507 ((3-exo)-8-benzoyl-N-(((2S)7-chloro-2,3-dihydro-1,4-benzodioxin-1-yl)methyl)-8-azabicyclo (3.2.1) octane-3-methanamine monohydrochloride) is a novel tropanemethanamine benzodioxane that displays antagonist activity at dopamine D2 receptors and agonist activity at 5-HT1A receptors....

  • Increased Occupancy of Dopamine Receptors in Human Striatum during Cue-Elicited Cocaine Craving. Wong, Dean F.; Kuwabara, Hiroto; Schretlen, David J.; Bonson, Katherine R.; Yun Zhou; Nandi, Ayon; Brašić, James R.; Kimes, Alane S.; Maris, Marika A.; Kumar, Anil; Contoreggi, Carlo; Links, Jonathan; Ernst, Monique; Rousset, Olivier; Zukin, Stephen; Grace, Anthony A.; Rohde, Charles; Jasinski, Donald R.; Gjedde, Albert; London, Edythe D. // Neuropsychopharmacology;Dec2006, Vol. 31 Issue 12, p2716 

    In all, 19 research subjects, with current histories of frequent cocaine use, were exposed to cocaine-related cues to elicit drug craving. We measured the change of occupancy of dopamine at D2-like receptors with positron emission tomography (PET) and inferred a change of intrasynaptic dopamine...

  • Pramipexole: In Restless Legs Syndrome. McCormack, Paul L.; Siddiqui, M. Saif A. // CNS Drugs;2007, Vol. 21 Issue 5, p429 

    âš´ Pramipexole is an oral, non-ergoline dopamine agonist with selectivity for the dopamine D3 receptor, which was recently approved in the EU and the US for the treatment of idiopathic restless legs syndrome (RLS) in adults. âš´ In a polysomnographic study, pramipexole 0.125, 0.25, 0.50...

  • Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease : A short commentary. Quinn, N. P. // Journal of Neurology;Jan2003, Vol. 250 Issue 1, p97 

    Comments on ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease. Effect of dopamine agonists on Parkinson's disease patients on chronic levodopa therapy; Equivalence between adjunctive ropinirole and bromocriptine.

  • Dopamine D3 Receptor Function and Cocaine Exposure. Blaylock, Brandi L; Nader, Michael A // Neuropsychopharmacology;Jan2012, Vol. 37 Issue 1, p297 

    The article reports on a study which shows the potentials of dopamine D[3] receptors for cocaine addiction treatment. The study found that the partial agonist CJB090 and dopamine D[3] receptor-selective compound PG619 elicited yawns similar to that D[3] -specific unconditioned behavior....

  • Dopamine D Receptors: Relevance for the Drug Treatment of Parkinson's Disease. Levant, B.; Ling, Z.D.; Carvey, P.M. // CNS Drugs;1999, Vol. 12 Issue 5, p391 

    The discovery of dopamine receptor subtypes provides an opportunity to develop receptor subtype-specific drugs which could improve the therapeutic index (TI) associated with dopamine replacement therapy in Parkinson's disease. The first generation ergot-derivative direct-acting dopamine receptor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics